Concentration-effect relationships and implications for trough-to-peak ratio

American Journal of Hypertension

Volumn 9, Issue 10 PART I, 1996, Pages

  Meredith, Peter A ^a   Elliott, Henry L ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antihypertensive drug dosing; Concentration effect relationships; Food and Drug Administration guidelines; Trough to peak blood pressure responses

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION;

EID: 0029906806     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(96)00266-x     Document Type: Article

References (13)

1. Meredith PA, Perloff D, Mancia G, Pickering T: Blood pressure variability and its implications for antihypertensive therapy. Blood Pressure 1995;4:5-11.
2. Elliott HL, Meredith PA: Trough:peak ratio: clinically useful or practically irrelevant? J Hypertens 1995; 13:279-283.
3. Zannad F: Trandolapril: how does it differ from other angiotensin converting enzyme inhibitors? Drugs 1993; 46(suppl 2):172-182.
4. Ménard J, Bellet M, Brunner HR: Clinical development of antihypertensive drugs: can we perform better? in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, 1st ed. Raven Press Limited, New York, 1990, pp 2331-2350.
5. Meredith PA, Donnelly R, Elliott HL: Prediction and optimisation of the antihypertensive response to nifedipine. Blood Pressure 1994;3:303-308.
6. Meredith PA, Reid JL: The use of pharmacodynamic and pharmacokinetic profiles in drug development for planning individual therapy. in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management. Raven Press, New York, 1995, pp 2771-2783.
7. Meredith PA, Elliott HL, Pasanisi F, et al: Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol 1985;20:101-106.
8. McMahon FG, Reder RF: The relationship of dose to antihypertensive response to verapamil-sustained release in patients with mild to moderate essential hypertension. J Clin Pharmacol 1989;29:1003-1007.
9. Francis RJ, Brown AN, Kler L, et al: Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and J Cardiovasc Pharmacol 1987;9:32-38.
10. Meredith PA: Therapeutic implications of drug 'holidays.' Eur Heart J 1996;17(suppl A):21-24.
11. Anderson A, Morgan O, Morgan T: Effectiveness of blood pressure control with once daily administration of enalapril and perindopril. Am J Hypertens 1994; 7:371-373.
12. Zanchetti A, Bianchi L, Bozza M, et al for the Italian Nifedipine GITS Study Group: Antihypertensive effects of nifedipine GITS on clinic and ambulatory blood pressures in essential hypertensives. J High Blood Pressure 1994;3:45-56.
13. Vaur L, Dutrey-Dupagne C, Boussac J, et al: Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995;26(1):127-131.